Future Market Insights2h
Global Direct Oral Anticoagulants Market Projected to Reach USD 71.78 Billion by 2032, Driven by FDA Approvals and Rising Thrombosis Cases
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
Stock World4h
EQS-News: QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery
QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...
PharmiWeb4h
QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
JD Supra19h
Classified (Bi-)Monthly: A Roundup of Class Action Decisions From Federal Appellate Courts July and August 2024
The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.
Future Market Insights21h
Global Hidradenitis Suppurativa Treatment Market Projected to Reach USD 1,240.9 Million by 2033, With a CAGR of 4.97%
Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, and Aristea Therapeutics. Sabyasachi Ghosh (Associate Vice ...
PharmiWeb23h
Global Progressive Fibrosing Interstitial Lung Disease Market Projected to Reach USD 8654.1 Million by 2033 at a 6.2% of CAGR
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
BioPharma Dive2d
Oral version of Novo diabetes drug protects heart health in large study
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.